Grail, Inc. (GRAL) Securities Class Action Lawsuit Update

• Company: Grail, Inc. (NASDAQ: GRAL)
• Lead Plaintiff Deadline: August 4, 2026
• Class Period: May 13, 2025 - February 19, 2026
• Stock Drop: February 20, 2026 - GRAL fell $51.32 (50.55%) to $50.21
• Lawsuit Type: Securities Class Action

Introduction

On June 5, 2026, a securities class action complaint was filed in the United States District Court for the Northern District of California against Grail, Inc. and three of its senior executives: Chief Executive Officer Robert P. Ragusa, President Joshua J. Ofman, and Chief Scientific Officer and International President Harpal S. Kumar. The lawsuit, brought on behalf of investors who purchased Grail common stock between May 13, 2025, and February 19, 2026, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

At the heart of the case is a story of scientific optimism that allegedly crossed the line into deception. Grail staked its reputation on Galleri, a blood-based multi-cancer early detection test, and the NHS-Galleri trial was the proving ground. The complaint alleges that defendants repeatedly made statements conveying confidence in the NHS-Galleri trial and its three-year design, including statements about its ability to evaluate or deliver results on the primary endpoint, a statistically significant reduction in Stage III and IV cancers. They pointed to "substantially higher" positive predictive values from the first screening round, touted results from the Pathfinder studies as sources of "confidence," and assured the market that the trial's three-year design was specifically sized "to be able to deliver a statistically significant result." The complaint alleges that these statements artificially inflated Grail's stock price by creating an overly optimistic impression of the trial's prospects ahead of the expected readout.

Then, on February 19, 2026, Grail disclosed the trial results. Grail disclosed that the NHS-Galleri trial had failed to achieve its primary endpoint. The primary endpoint of a statistically significant Stage III-IV reduction "was not observed." The company's own Chief Scientific Officer conceded the trial "probably need[ed] a longer follow-up time" and acknowledged that "with the benefit of hindsight, we probably should have allowed for a longer follow-up period." The market's verdict was swift and devastating: Grail's stock plummeted from $101.53 to $50.21 in a single trading session, erasing more than half of its value.

Backdrop and Business Context

Grail, Inc. originated from Illumina and became an independent Nasdaq-listed company in June 2024 after Illumina spun off the business following antitrust scrutiny and regulatory divestiture requirements.

Grail develops and commercializes Galleri, a blood-based multi-cancer early detection test that analyzes methylation patterns in cell-free DNA to screen for signals from more than 50 cancer types. The test, priced at roughly $949 per draw, is prescription-only and intended for adults aged 50 and older as a complement to standard screenings such as mammography and colonoscopy. Grail reported approximately $147.2 million in total revenue for 2025, a 17% increase year over year, driven by over 185,000 Galleri tests. Grail is headquartered in Menlo Park, California, with additional locations in North Carolina, Washington, D.C., and the United Kingdom.

Grail operates in the developing multi-cancer early detection segment of the broader liquid biopsy market. Its competitive differentiation rests on the Galleri test's breadth of cancer coverage and its large-scale clinical evidence base, anchored by the 140,000-participant NHS-Galleri randomized controlled trial. According to the complaint, however, that very trial became the vehicle for the company's alleged concealment of material risks regarding Galleri's ability to demonstrate a population-level reduction in late-stage cancers within the study's timeframe.

Promises Made vs. Reality

Throughout the Class Period, Grail's leadership constructed a narrative of scientific momentum and trial confidence that the complaint alleges concealed material risks and design limitations regarding whether the NHS-Galleri study could achieve its primary endpoint within the trial's timeframe.

The story began on May 13, 2025, when Grail debuted what it called "Positive Top-Line Results from the Prevalent Screening Round of the NHS-Galleri Trial." The company announced that the first round of blood draws showed "a substantially higher positive predictive value (PPV) than that observed in the PATHFINDER study," where Galleri had demonstrated a PPV of 43%. Kumar told investors the results were "very encouraging" and emphasized the trial's design as "3 annual blood draws plus 12 months of follow-up" to evaluate Galleri's ability to diagnose cancer at an earlier stage. Ofman reinforced the message with characteristic directness: "Now let's be clear, Galleri is working in the real world. We are detecting clinically meaningful cancers and early-stage cancers in asymptomatic adults." When analysts pressed for more granular data, Kumar explained that sharing detailed first-round results would "risk the integrity of the trial as a whole," positioning the withholding of information as a mark of scientific rigor rather than a potential concealment of unfavorable trends.

As the months progressed, Defendants reinforced rather than tempered their confidence. During the August 12, 2025 earnings call, Ofman characterized the top-line findings from NHS-Galleri and Pathfinder 2 as data that "confirm and extend what we already know about our multi-cancer early detection technology." When an analyst asked Kumar directly about the trial's statistical powering, he assured investors that "the size of the study was set to be able to deliver a statistically significant result" on the primary endpoint of a reduction in Stage III and IV cancers, adding, "we will see what that reduction ends up being." Ragusa framed the upcoming readout as "a great calling card" for international expansion, while Kumar predicted the results would "provide us with the data to really turn those conversations into meaningful opportunities."

The confidence only intensified in the fall. At the Morgan Stanley Global Healthcare Conference on September 9, 2025, Ragusa reminded investors the company was "really looking forward" to the full NHS-Galleri readout, describing it alongside Galleri's clinical utility and FDA submission timeline. On October 20, 2025, Ofman acknowledged that Pathfinder 2 results could not "directly" predict stage shift outcomes from NHS-Galleri, but nonetheless emphasized that the dramatically increased cancer detection rate and higher PPV "give us a lot of confidence in the performance." Kumar added that the proportion of cancers found at stages 1 and 2 in Pathfinder 2 "really do encourage me" about NHS-Galleri's prospects. By November 12, 2025, Ofman was still reminding investors of the “substantially higher positive predictive value” from the first screening round, and Kumar reiterated that “it isn’t possible to look at the sort of broad utility measure of Stage 3 and 4 reduction with only 1 year of data. That has to come with 3 years of data,” which the complaint alleges contributed to the misleading impression that the three-year design would be adequate. The following day, at the Analyst/Investor Day, an advisory board member described the study's endpoint framework and analogized it to HPV vaccination, supporting a favorable narrative around the clinical utility framework.

Then, according to the complaint, the alleged truth emerged on February 19, 2026. Grail disclosed that "the primary endpoint of statistically significant Stage III-IV reduction was not observed." Kumar conceded the company "probably need[ed] a longer follow-up time" and acknowledged that "with the benefit of hindsight, we probably should have allowed for a longer follow-up period." Yet after the trial’s failure, the same executives recharacterized the study as having been “a very short trial with a very ambitious endpoint,” a design limitation the complaint alleges defendants had not adequately disclosed during the Class Period. The complaint alleges that these later explanations contrasted with earlier statements that the study was sized to deliver a statistically significant result.

As alleged in the complaint, the pattern of statements from May 2025 through February 2026 created a materially misleading impression of confidence in the NHS-Galleri trial's trajectory, while defendants possessed access to detailed first-round screening data, potential trendline information, and other non-public information about the study's prospects that they withheld from the investing public.

Timeline of Alleged Misconduct and Disclosures

Class Period: May 13, 2025 - February 19, 2026, inclusive.

May 29, 2024: NHS England announces it will await final three-year results from the NHS-Galleri trial before determining whether to initiate a pilot of the Galleri test, declining to accelerate implementation based on first-year data.

May 13, 2025: Class Period opens. Grail issues a press release reporting Q1 2025 results and announces "Positive Top-Line Results from the Prevalent Screening Round of the NHS-Galleri Trial," highlighting a substantially higher PPV than Pathfinder. During the earnings call, Kumar describes results as "very encouraging," Ofman states "Galleri is working in the real world," and Ragusa expresses the company is "very pleased." Defendants decline to share detailed data, citing trial integrity.

August 12, 2025: Grail reports Q2 2025 results. During the earnings call, Ofman states the NHS-Galleri and Pathfinder 2 findings "confirm and extend" what is known about Galleri. Kumar affirms the study was sized "to be able to deliver a statistically significant result" on the primary endpoint.

September 9, 2025: Defendant Ragusa presents at the Morgan Stanley Global Healthcare Conference. He promotes the NHS-Galleri full readout expected mid-2026 as a key catalyst for global market expansion, describing it as a "great calling card."

October 20, 2025: During a special call discussing Pathfinder 2 results, Ofman states the data give Grail "a lot of confidence in the performance" of Galleri, while acknowledging no direct inference to NHS-Galleri's stage-shift endpoint can be drawn. Kumar adds that Pathfinder 2 findings "really do encourage me."

November 12, 2025: Grail reports Q3 2025 results. Ofman reminds investors of the substantially higher PPV from the NHS-Galleri prevalent screening round. Kumar reiterates that the Stage III-IV reduction metric "has to come with 3 years of data," which the complaint alleges contributed to the misleading impression that the three-year design would be adequate.

November 13, 2025: Grail hosts Analyst/Investor Day. An advisory board member, Peter Sasieni, elaborates on the study design and draws analogies to HPV vaccination to support the clinical utility framework.

February 19, 2026: Alleged corrective disclosure. Grail announces that the "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri trial. During the earnings call, Kumar concedes the company "probably need[ed] a longer follow-up time" and admits that "with the benefit of hindsight, we probably should have allowed for a longer follow-up period." Ofman characterizes NHS-Galleri as "actually a very short trial with a very ambitious endpoint." Grail's stock price closes at $101.53.

February 20, 2026: Grail's stock price falls to $50.21, a decline of approximately 50.55% in a single trading session.

Investor Harm and Market Reaction

The market's response to Grail's February 19, 2026 disclosure was immediate and catastrophic. From a closing price of $101.53 per share on February 19, 2026, Grail's stock collapsed to $50.21 per share on February 20, 2026, a decline of approximately $51.32 per share, or about 50.55%, in a single day of trading. The loss erased roughly half of the company's market capitalization overnight.

The complaint alleges that the severity of the decline reflected the materiality of defendants' prior statements and omissions. Analysts who had built investment theses around a positive readout were forced into rapid reassessment. Baird, which had initiated coverage just days earlier on February 17, 2026, slashed its price target by more than 27% to $31, noting the study's "missing its primary endpoint of demonstrating a statistically significant reduction for stage III-IV cancer" and warning that the result "likely decreases (but does not necessarily eliminate) the likelihood of broader NHS adoption in the near-term." Canaccord Genuity cut its price target more than 20%, from $105 to $80, citing "increased risk" and reduced revenue potential while highlighting that the trial "did not achieve statistical significance with respect to the study's primary endpoint."

The breadth and speed of these analyst downgrades, combined with the magnitude of the stock price collapse, underscore the materiality of defendants' prior statements. The complaint alleges that Grail's stock traded at artificially inflated levels because of defendants' statements and omissions regarding the NHS-Galleri readout. According to the complaint, when the alleged truth emerged, the artificial inflation allegedly embedded in the stock price was removed.

Litigation & Procedural Posture

The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against all defendants, and under Section 20(a) of the Exchange Act against the Individual Defendants as controlling persons of Grail.

The defendants are Grail, Inc. and executives Robert P. Ragusa (CEO), Joshua J. Ofman (President), and Harpal S. Kumar (Chief Scientific Officer and International President).

Scienter allegations center on the defendants' access to non-public information concerning the probability of the NHS-Galleri trial achieving its primary endpoint. The complaint alleges that defendants possessed detailed first-round screening data, including trend information regarding Stage III-IV cancer reductions, that they refused to disclose publicly while simultaneously offering reassurances about the trial's trajectory. Their scienter is further evidenced by the contrast between their Class Period statements, including that the study was specifically sized "to be able to deliver a statistically significant result," and their post-disclosure concessions that the trial was "actually a very short trial with a very ambitious endpoint" that "probably should have allowed for a longer follow-up period." The complaint also highlights that the NHS itself had declined to accelerate implementation after reviewing the same first-year data that Grail was publicly praising, a fact defendants disclosed but did not reconcile with their optimistic framing. No insider sales or confidential witness testimony is cited in the complaint.

Procedurally, the case was filed on June 5, 2026, and seeks class certification under Federal Rule of Civil Procedure 23(a) and (b)(3). Lead plaintiff submissions are due August 4, 2026. Grail's common stock traded on the Nasdaq during the Class Period, and the complaint invokes the fraud-on-the-market presumption of reliance based on the efficiency of the market for Grail shares, citing active trading, analyst coverage, and rapid price reactions to material news.

SEC Filings & Risk Factors

The complaint does not focus on specific SEC periodic filings as independent vehicles of misrepresentation. Instead, the alleged misstatements arise primarily from Grail's press releases, earnings calls, conference presentations, and shareholder communications during the Class Period. The complaint references Grail's public filings with the SEC generally, noting that the Individual Defendants possessed the power and authority to control the contents of the company's SEC reports, press releases, and analyst presentations, and that they had access to copies of these materials prior to or shortly after issuance.

The core filing-related allegation concerns not what Grail's periodic filings disclosed, but what the company's public communications omitted. Specifically, the complaint alleges that defendants withheld detailed data from the NHS-Galleri trial's first screening round, including potential trend information regarding Stage III-IV cancer reductions, while simultaneously making affirmative statements of confidence about the trial's trajectory. Defendants characterized the withholding of detailed results as necessary to "safeguard" the "integrity of the trial as a whole" and the "interest of the participants," framing the information gap as responsible stewardship rather than selective disclosure.

The complaint alleges a pattern of selective disclosure in defendants' public communications. When discussing the NHS-Galleri trial, defendants consistently foregrounded positive metrics, particularly the "substantially higher" PPV relative to Pathfinder, while characterizing uncertainties about the primary endpoint in hypothetical or forward-looking terms. The complaint alleges that Kumar's August 2025 statement that the study was sized "to be able to deliver a statistically significant result" contributed to a misleading impression that the trial was adequately designed to achieve its primary endpoint. Yet after the trial’s failure, the same executives recharacterized the study as having been “a very short trial with a very ambitious endpoint,” a design limitation the complaint alleges defendants had not adequately disclosed during the Class Period. The complaint alleges this pattern was materially misleading because it concealed known information about the probability of achieving the primary endpoint while presenting the trial's design as sufficient to do so. The materiality of the omitted information is underscored by the 50.55% stock price decline upon disclosure, as well as the immediate and substantial analyst downgrades that followed.

How to Join the Grail, Inc. (GRAL) Class Action

• Confirm you purchased GRAL shares during the May 13, 2025 to February 19, 2026 class period
• Review the allegations and eligibility requirements in the pending securities class action
• Gather trade confirmations and brokerage records documenting purchases or losses
• Consult counsel regarding lead plaintiff deadlines, eligibility, and recovery rights
• Click here to check eligibility

Disclaimer: Attorney Advertising. This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.